Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of FSN-011-01 plus estrogen in Japanese women with menopausal disorder and uterus
jRCT2080223763Phase 3Completed
- Sponsor
- Fuji Pharma Co., Ltd.
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of progesterone in menopause, sponsored by Fuji Pharma Co., Ltd. Primary endpoint: Endometrial hyperplasia incidence at 52 weeks. Started Dec 2017; status: completed.
02
Drugs
progesterone
03
Conditions
menopause
Beyond the preview
Go deeper on jRCT2080223763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223763.